Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Other Disease Areas
Filter     Order     Display # 
Date Item Title
05 Apr 2006 Threshold Pharmaceuticals Completes Enrollment in Phase 3 Study for the Treatment of Benign Prostatic Hyperplasia
05 Apr 2006 Quest PharmaTech Inc. provides clinical trial and corporate update
04 Apr 2006 PTC Therapeutics Announces Interim Phase 2 Results Of PTC124 In Cystic Fibrosis
04 Apr 2006 TopoTarget reports promising Phase II trial results with Avugane™ in acne vulgaris
04 Apr 2006 Edison Pharmaceuticals Announces FDA Grants EPI-A0001 Orphan Drug Designation for Inherited Mitochondrial Respiratory Chain Diseases
04 Apr 2006 Can-Fite to Initiate Clinical Studies to Test Efficacy of CF101 in Treating Dry Eyes Syndrome
04 Apr 2006 Alba Therapeutics Corporation Completes Phase I for AT-1001
04 Apr 2006 LAB International completes patient enrollment in Fentanyl TAIFUN(R) Phase IIa trial
03 Apr 2006 Retisert slows progression of Diabetic Retinopathy in Diabetic Macular Edema trials
30 Mar 2006 Axcan submits FDA amendment to its new drug application for HELIZIDE
30 Mar 2006 Genaera Corporation Presents Encouraging Data on Bilateral Visual Acuity in Subjects From EVIZON Phase II Trials
29 Mar 2006 FDA Panel Recommends Approval of ADEPT® Adhesion Reduction Solution
27 Mar 2006 Eisai Applies for a New Indication of Non-Erosive Gastro-Esophageal Reflux Disease for Pariet(R) a Proton Pump Inhibitor, in Japan
27 Mar 2006 Santarus Receives FDA Approval for ZEGERID with Magnesium Hydroxide Chewable Tablets
27 Mar 2006 Bio3 Research and Daxley Group Enter into License Agreement for Biocysan™ in End-Stage Renal Disease
25 Mar 2006 Allergan Receives Positive Opinion for GANFORT(R) (LUMIGAN(R)/Timolol Combination) in European Union
25 Mar 2006 Novartis provides update on regulatory status of Zelnorm® in Europe
24 Mar 2006 Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF
23 Mar 2006 Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure
23 Mar 2006 NEXIUM® Shown to Reduce Gastric Ulcers in at-risk Patients Using Long-term NSAIDS
22 Mar 2006 Indevus Completes Enrollment in Second Phase III Trial for SANCTURA XR(TM)
21 Mar 2006 Data Safety Monitoring Board Recommends Continuation of Medidur™ Phase III Clinical Trial
21 Mar 2006 MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal Program; Patient Enrollment Expected To Conclude By Year-End
21 Mar 2006 Threshold Pharmaceuticals Completes Enrollment in a Phase 2 Study for the Treatment of Benign Prostatic Hyperplasia
20 Mar 2006 SurModics Completes Enrollment of Phase I Clinical Trial of the I-vation(TM) Intravitreal Implant
17 Mar 2006 OSMOPREP™ Tablets Granted FDA Marketing Approval
15 Mar 2006 Surface Logix Commences Phase I Trial For Novel Gastrointestinal-Specific MTP Inhibitor
15 Mar 2006 Neurotech Announces Publication of NT-501 Phase I Results in Proceedings of the National Academy of Sciences
13 Mar 2006 Compound From Pharmacopeia Collaboration Shows Clinical Activity in Phase I Trial
10 Mar 2006 OccuLogix Reports Positive MIRA-1 Analysis Results
09 Mar 2006 Kamada Receives Final FDA Approval to Commence Phase III Clinical Trials of API with Congenital Emphysema Patient
07 Mar 2006 Genvec Completes Enrollment In Adpedf Clinical Study For Macular Degeneration
04 Mar 2006 Results of Large Phase IV Study Show Differin (adapalene gel) Gel, 0.1% Works Well in Combination With Systemic or Other Topical Agents
03 Mar 2006 Advanced Magnetics Announces Design of Phase III Iron Therapy Program for Ferumoxytol
02 Mar 2006 NicOx compound demonstrates excellent preclinical results in Pfizer glaucoma collaboration
02 Mar 2006 Alcon Laboratories withdraws its application for RETAANE
02 Mar 2006 Novartis seeks European approval of Lucentis® for the treatment of patients with wet age-related macular degeneration (AMD)
02 Mar 2006 Genaera Announces Interim Evizon™ Phase Ii (Msi-1256f-209) Data
01 Mar 2006 Genentech Granted Six-Month Priority Review for Lucentis for the Treatment of Wet Age-Related Macular Degeneration
28 Feb 2006 Santarus Receives FDA Approval for ZEGERID Capsules; First and Only Immediate-Release Proton Pump Inhibitor in Convenient Capsule Form
28 Feb 2006 CollaGenex Pharmaceuticals' Announces Filing of Marketing Authorization Application for ORACEA(TM) with the Medicines & Healthcare Products Regulatory Agency in the United Kingdom
25 Feb 2006 Alcon Receives Positive Opinion for DuoTrav(TM) Eye Drops Solution from CHMP
24 Feb 2006 New clinical study for treatment of diabetic foot ulcers
24 Feb 2006 DUSA pharmaceuticals reports statistically significant results from phase II clinical trial for PDT of photodamaged skin
24 Feb 2006 Systemic Safety Profile of Macugen(R) (pegaptanib sodium injection) Maintained Throughout Two Years with No Increased Risk of Cardiovascular Events
22 Feb 2006 Positive Phase II Clinical Trial Results Announced by Antares Pharma; Anturol(TM) Oxybutynin ATD(TM) Gel System for Overactive Bladder
22 Feb 2006 Axcan announces outcome of ITAX International Phase III clinical trial
21 Feb 2006 ISTA Pharmaceuticals Announces Positive Preliminary Results From Phase IIb Trial of Ecabet Sodium for the Treatment of Dry Eye Syndrome
17 Feb 2006 BioSante Pharmaceuticals Announces Bio-E-Gel™ NDA Submission
16 Feb 2006 Organon to close the LIFT study
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 901 - 950 of 985

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics